PSIL News | Roxom Stocks

1 BTC

- USD

Loading market data...

AUM

N/A

Volume

19.68K

Yield

33.85%

Chart Earnings News About Dividends Insider Filings

These 3 Psychedelic Stocks Activated After Trump’s Executive OrderTrump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.Investing.com · Apr 27, 2026

Cannabis And Psychedelics Industries: Summer's Over, Where Are We?The cannabis industry is awaiting a decision on rescheduling cannabis, which could impact its financial and regulatory landscape. The psychedelics industry is navigating the aftermath of a setback in MDMA research for PTSD, leading to potential consolidation and strategic shifts.Benzinga · Aug 28, 2024

Top and Flop ETFs of the First HalfWe have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.Zacks Investment Research · Jun 28, 2024

Best and Worst ETF Zones of Q2Technology remained the best-performing sector of the second quarter on the AI drive while energy lagged.Zacks Investment Research · Jun 25, 2024

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD TreatmentA panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, ...Full story available on Benzinga.comBenzinga · Jun 5, 2024

Top & Flop ETFs of AugustAugust was an average-to-downbeat month for investors, mainly due to rising rates.Zacks Investment Research · Aug 31, 2023

EXCLUSIVE: Investing In The Unique Growth Market Of PsychedelicsThe global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. Several esteemed professionals in the space talked about ways to get exposure Thursday (April 13) at Benzinga's Psychedelics Capital Conference in Miami Beach. Psyched For Psychedelics: The global psychedelics drugs space is expected to grow at a 13.3% CAGR through 2029. The market is still in its infancy, but with promising potential to help various mental health issues, long-term investors could be handsomely rewarded. Maria Velkova, managing partner of Tabula Rasa Ventures, takes a holistic approach to investing in psychedelics. She reminded the crowd that drug development requires the collection of clinical data and the development of infrastructure, which takes time, but there is a well-defined path to market, she said. One of her favorite investments in the space is psychedelics insurance company Enthea. "It's a really incredible company and a really key company in the space because one of the biggest hurdles we are going to face is ...Benzinga · Apr 13, 2023

Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And MoreMDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data MAPS Public Benefit Corporation shared positive topline results from an observational follow-up of its two Phase 3 studies on the long-term safety and efficacy of MDMA-assisted therapy for PTSD. The findings show participants held a durable response within at least six months and in some cases a year or more, post-treatment with MDMA-assisted therapy. "These results are consistent with previously published Phase 2 data demonstrating the sustained effect of MDMA-assisted therapy at least 12 months following treatment and suggest the acute treatment effect could last even longer," said MAPS PBC’s CEO, Amy Emerson. Keep reading HERE. UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage Clinical-stage private biotech company Beckley Psytech Ltd. has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment. CEO ‍Cosmo Feilding Mellen said the company’s aim to treat substance use disorders has led them to “the rigorous scientific ...Benzinga · Apr 11, 2023

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And MoreTwo Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and psilocybin as an alternative to treat mental health conditions. The measures, which received unanimous votes and now are heading to the Senate floor, received supportive testimony from the governor’s office, reported Marijuana Moment. Sponsored by Sen. Chris Lee (D), Bill SB 1531 aims to create a “beneficial treatments advisory council” that would respond to the governor’s Office of Wellness and Resiliency (OWR). Once enacted, the measure would create an advisory council tasked with exploring state and federal regulations on certain psychedelics, in addition to reviewing scientific literature related to using them for mental health treatment. Moreover, the advisory council would require the creation of a “long-term strategic plan to ensure the availability of therapeutic psilocybin, psilocybin-based products, and [MDMA] that are safe, accessible, and affordable for adults 20 years of age or older.” Sen. Ron Kouchi (D), who sponsors a separate bill, seeks to establish a statewide task force to specifically study the therapeutic benefits of psilocybin. Continue reading HERE. Minnesota Takes Action to Legalize Psychedelics Meanwhile, Minnesota lawmakers introduced a measure that would set up a task force to study and give recommendations on the legalization of substances like psilocybin, MDMA and ibogaine was introduced recently by Minnesota House members, as first reported by Marijuana Moment. Under HF 1884, sponsored by Rep. Andy Smith (D), a "Psychedelic Medicine Task Force" comprising 23 members that would be assigned to advising the "legislature on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state." Continue reading HERE. 2C-B Vs. Psilocybin: New Study Shares Insightful Trial Results On The Mescaline-Derived Psychedelic's Effects A new clinical trial assessed the immediate acute effects of 2C-B hallucinogenic phenethylamine compared to psilocybin on subjective experience, mood and cognition. The study, conducted by Netherlands’ University of Maastricht, had a total of 22 psychedelic-experienced volunteers divided into three cohorts: one administered 20 milligrams of 2C-B, another 15 milligrams of psilocybin, and a third placebo. Both 2C-B and psilocybin’s effects in participants included dysphoria, subjective impairment, auditory alterations and affective elements of ego dissolution, and yet the duration of 2C-B’s effects was, according to participants’ self-reports, shorter ...Benzinga · Feb 28, 2023

Best-Performing ETFs of August Up At Least 15%These ETFs gained at least 15% in the downbeat month of August.Zacks Investment Research · Sep 2, 2022

PSILAdvisorShares Psychedelics ETF

PSIL

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any PSIL yet.

Related Tickers

Earnings

Dividends

Last · Dec 22Quarterly

Amount$1.68

Yield8.46%

Annual$1.68

Volume

19.68K